Hims & Hers (HIMS) Sees Analyst Optimism Following Novo Resolution

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the 11 Best Day Trading Stocks to Buy Now.

Investment bank Barclays discussed Hims & Hers Health, Inc. (NYSE:HIMS)’s shares on March 11th. It raised the share price target to $29 from $25 and kept an Overweight rating on the stock. Barclays commented that the fact that Hims & Hers Health, Inc. (NYSE:HIMS)’s shares had performed well after its agreement with Novo Nordisk indicated that the firm’s legal woes were behind it. Barclays added that the market appeared to be underestimating the opportunities for new products from new products.

Hims & Hers (HIMS) Sees Analyst Optimism Following Novo Resolution

Barclays coverage came after Novo Nordisk announced that it had decided to drop its legal action against Hims & Hers Health, Inc. (NYSE:HIMS) for what the healthcare company dubbed an illegal compound dispute. Novo had taken the action after Hims & Hers Health, Inc. (NYSE:HIMS) had announced that it would sell its own weight loss pill. The development came after the pair had ended their partnership last year to provide discounted weight loss shots to Hims & Hers Health, Inc. (NYSE:HIMS)’s customers.

Hims & Hers Health, Inc. (NYSE:HIMS) is a health platform that offers prescription and non-prescription products to consumers. The firm is headquartered in San Francisco, California.

While we acknowledge the risk and potential of HIMS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than HIMS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None.  Follow Insider Monkey on Google News.